ПРИМЕНЕНИЕ АЛГОРИТМИЗИРОВАННОЙ СИСТЕМЫ FRAX ДЛЯ ПРОГНОЗИРОВАНИЯ РИСКА ОСТЕОПОРОТИЧЕСКИХ ПЕРЕЛОМОВ
Ключевые слова:
остеопоротик синишлар, хавф, FRАХ, ахоли скрининги, даволаш чегаралариАннотация
Остеопоротик синишларнинг кўпайиб бораётгани ахоли орасида суяк синишлари хавфи башоратини бахолаган холда олдини олиш ва ўз вақтида давосини бошлаш долзарб муаммо хисобланади
Библиографические ссылки
1. Гладкова Е.Н., Лесняк О.М., Закроева А.Г., и соавт. Роль и место калькулятора FRAX в принятии решения об инициации лечения остеопороза: анализ регистра центра остеопороза. Остеопорози остеопатии. 2022; 25 (2) 4-13.
2. Закроева А.Г., Бабалян В.Н., Габдулина Г.Х. Состояние проблемы остеопороза в странах евразийского региона Остеопороз и остеопатии. 2020; 23(4):19-29.
3. Умаров Ф.Х., Уразбаев Ж.Д. Факторы риска низкоэнергетического перелома проксимального отдела бедренной кости (аналитический обзор литературы). Травматология, ортопедия и реабилитация. 4. Baró F, Cano A, Sánchez Borrego R, et al. Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture. FROSPE Study Group. Menopause. 2012 (11):1193-1199. 5. Bhujade R, Srivastava A, Chinchodkar K.N, et al. Cross-sectional osteoporotic risk prediction with the FRAX without BMD in male and female patients attending OPD in a community health center of Bihar. J Family Med Prim Care. 2022;11(6):2345-2350. 6. Briot K, Paternotte S, Kolta S, et al. FRAXH: Prediction of Major Osteoporotic Fractures in Women from the General Population: The OPUS Study. PLoS ONE; 2013; 8(12): e83436
7. Camacho P.M, Petak S.M, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology/ Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Update. Endocr Pract. 2020; 26:1-46.
8. Charatcharoenwitthaya N, Jaisamrarn U, Songpatanasilp T., et al. Summary of the Thai Osteoporosis Foundation (TOPF) Clinical Practice Guideline on the diagnosis and management of osteoporosis 2021. Osteoporos Sarcopenia. 2023;9(2):45-52.
9. Clinical guideline for the prevention and treatment of osteoporosis. The National Osteoporosis Guideline Group (NOGG) 2024; 74. Available from:
https://www.nogg.org.uk/sites/nogg/download/NOGG-Guideline-2024.pdf?v4 10. Compston J., Cooper A., Cooper C., et al. National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. 11. Favarato M.H.S., Almeida M F., Lichtenstein A., et al. Risk of osteoporotic fracture in women using the FRAX tool with and without bone mineral density score in patients followed at a tertiary outpatient clinic ‒ An observational study. Clinics (Sao Paulo). 2022;77:100015.
12.Fuggle N.R., Beaudart C., Bruyère O., et al. Evidence-Based Guideline for the management of osteoporosis in men. Nat Rev Rheumatol. 2024; 20(4): 241-251.
13. Goldshtein I., Gerber Y., Shalom S.I., Leshno M. Fracture risk assessment with FRAX using real world data in population based cohort from Israel. Am J Epidemic. 2018;187:94–102
14. Cranney A., Jamal S.A., Tsang J.F., et al. Low bone mineral density and fracture burden in postmenopausal women. Can Med Assoc J. 2007;177:575-580.
15. Grygorieva NV, Kovalenko VM, Кorzh MO, et al. Ukrainian Association of Osteoporosis. Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2025; 20(1): 31
16. Inderjeeth C.A., Raymond W.D. Case finding with GARVAN fracture risk calculator in primary prevention of fragility fractures in older people. Arch Gerontol Geriatr. 2020; 86: 103940.
17. International Osteoporosis Foundation. About Osteoporosis. Available from: https://www.osteoporosis.foundation/health-professionals/about-osteoporosis. Accessed: 2023 Aug 25
18. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int. 1994;4:368-381
19. Kanis J.A., Johnell O., Oden A., et al. Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int. 2000; 11:120-127
20. Kanis J.A., Oden A., Johnell O., et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001; 12:417-427
21. Kanis J.A., Johnell O., De Laet C., et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002; 17:1237-1244.
22..Kanis J.A., Johansson H., Oden A., et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:1029-1037
23. Kanis J.A., Johnell O., De Laet C. et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35 (2): 375-382.
24. Kanis J.A., Johnell O., Oden A., et al. FRAX and the assessment of fracture probability in men &women from UK. Osteoporos Int. 2008;19:385-397
25. Kanis J.A., Johansson H., Oden A, McCloskey E.V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22:809-816.
26. Kanis JA, Johansson H, Harvey NC, Mccloskey EV. A brief history of FRAX. Arch Osteoporos. 2018
27. Kanis J.A,, Harvey N.C., McCloskey E., et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31:1-12.
28. Kanis J.A., Norton N., Harvey N.C. et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 2021;16, 82.
29. Kanis J.A., McCloskey W.D., Leslie et al. Previous fracture and subsequent fracture risk: A meta-analysis to update FRAX. Osteoporos Int. 2023; 34(12): 2027-2045.
30. Ke Y., Hu H., Zhang J., et al. Alcohol Consumption and Risk of Fractures: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Adv Nutr. 2023;14(4):599-611.
31. LeBoff M. S., Greenspan S.L., Insogna K.L., et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33 (10): 2049-2102.
32. Livingstone S.J., Guthrie B., McMinn M., et al. Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. Lancet Healthy Longev. 2023; 4(1): e43-e53
33. McCloskey E. V., Johansson H., Harvey N.C., et al. SCOOP Study Team. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study. J Bone Miner Res. 2018; 33(6):1020-1026.
34. McCloskey E.V., Borgstrom F., Cooper C., et al. Short time horizons for fracture prediction tools: time for a rethink. Osteoporos Int. 2021;32(6):1019-1025.
35. McCloskey E. V., Harveyc N. C., Johanssona H. M., et al. Fracture risk assessment by the FRAX model. Climacteric. 2022; 25 (1): 22-28.
36. Merlijn T., Swart K.M.A., Van Der Horst H.E., et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020; 31: 251-257.
37.National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available from: www.nof.org/files/nof/public/content/resource/862/ files/392.pdf. Accessed January 28, 2013
38. Parsons C.M., Harvey N., Shepstone L., et al. Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int. 2020;31(1):67-75.
39. Paskins Z, Ong T, Armstrong DJ. Bringing osteoporosis up to date: time to address the identity crisis (in eng) Age Ageing. 2020; 49: 329–331.
40. Rubin K.H., Rothmann M.J., Holmberg T., et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 2018; 29(3): 567-578.
41. Schini M., Johansson H., Harvey N.C., et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024; 47(3): 501-511.
42. Shepstone L., Lenaghan E., Cooper C., et al. Screening in the community to reduce fractures in older women (SCOOP): a randomized controlled trial. Lancet. 2018; 391(10122): 741-747
43. Szoltysik A.N., Miodonska Z., Zarzeczny R., et al. Osteoporosis in polish older women: Risk factors and osteoporotic fractures:A cross sectional study. Int J Environ Res Public Health. 2020;17:3725
44. Tan T.H.A., Johansson H., Harvey N.C., et al. Assessment of fracture risk with FRAX and FRAXplus.Gac Med Mex. 2024;16 0(4): 363-373.
45.World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. Geneva: World Health Organization; 1994. WHO Technical Report Series, 843 Available from: http://whqlibdoc.who.int/trs/who_trs_843.pdf,
46. Zhang N., Liu Y.J., Yang C., et al. Association between cigarette smoking and mortality in patients with hip fracture: A systematic review and meta-analysis. Tob Induc Dis. 2022; 20:110.
